Selumetinib is approved by the FDA on April 10, 2020, for the treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas.

Selumetinib is primarily used in the treatment of specific types of cancer, particularly in patients with mutations in the BRAF gene. It is employed for conditions such as neurofibromatosis type 1 (NF1) and certain pediatric brain tumors.

Selumetinib is primarily administered orally, typically in the form of capsules. The healthcare provider will determine the dosage and duration of treatment based on the specific infection and individual factors.

Selumetinib may result in various side effects, including cardiac issues, eye problems like changes in vision, skin reactions such as rash and dryness, gastrointestinal disturbances like nausea and diarrhea, the potential impact on liver function, musculoskeletal problems like muscle pain, hypertension, increased risk of bleeding, and potential harm to a developing fetus.

Selumetinib might cause heart-related problems. Some patients may experience changes in vision, such as blurred vision or difficulty focusing. Skin-related side effects like rash, dry skin, or hair color or texture changes can occur. Some patients may experience increased blood pressure.

It is essential to monitor heart function regularly while taking Selumetinib. Eye exams before and during treatment are often recommended. Managing these symptoms through diet and medications may be necessary. Regular liver function tests are typically recommended. Monitoring blood pressure regularly is important.

Regular monitoring of heart function, including ECGs and cardiac assessments, may be necessary due to potential heart-related side effects while using Selumetinib. Periodic eye exams are recommended as this medication might cause vision changes or retinal vein occlusion. Patients require monitoring for signs of interstitial lung disease (ILD) or breathing difficulties. Monitoring liver function through blood tests is essential due to the potential for elevated liver enzymes or liver damage.  Live vaccines should generally be avoided during treatment due to potential complications.  Regular monitoring might be necessary for individuals with existing endocrine conditions. Discuss with a healthcare professional regarding other medications, including over-the-counter drugs, herbal supplements, or vitamins, to avoid potential interactions with this medication.

1. MARC R THEORET, Food and Drug Administration (FDA),[Revised on April 2020] [ Accessed on 15th Nov 2023]
2. AstraZeneca UK Limited, Electronic medicines compendium (EMC), [ Revised on 15 Mar 2023] [ Accessed on 15th Nov 2023], https://www.medicines.org.uk/emc/product/12948/pil#gref

The drug information on this page is not a substitute for medical advice. It is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you can receive this treatment.